- $329.81m
- $36.76m
- 55
- 42
- 14
- 30
Annual balance sheet for Tourmaline Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 39 | 149 | 244 | 181 | 203 |
| Net Total Receivables | 0 | 0.374 | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 40.8 | 151 | 247 | 186 | 209 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.13 | 2.01 | 4.8 | 7.99 | 0.57 |
| Other Long Term Assets | |||||
| Total Assets | 41.9 | 153 | 251 | 194 | 210 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.29 | 3.4 | 7.99 | 11.5 | 5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.35 | 4.77 | 8.61 | 13.7 | 5.25 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 39.6 | 148 | 243 | 180 | 205 |
| Total Liabilities & Shareholders' Equity | 41.9 | 153 | 251 | 194 | 210 |
| Total Common Shares Outstanding |